Diversey, Inc., a global leader in healthcare and infection prevention solutions, has received confirmation through third-party testing that MoonBeam 3 UV-C disinfection technology is effective in just seconds against SARS-CoV-2, which causes COVID-19.
MoonBeam 3 is an ultraviolet-C disinfection device that adds assurance beyond manual cleaning and disinfection. This portable, powerful solution disinfects quickly, reliably and responsibly. MoonBeam 3 is cost-effective and designed for fast disinfection of public and high-risk areas. The system offers three individually-adjustable arms that can be positioned at almost any angle, optimizing disinfection energy to allow dosing of both horizontal and vertical surfaces, in just 3 minutes.
MoonBeam 3 has undergone third-party testing against several microorganisms including enveloped viruses, small non-enveloped viruses, bacteria and bacterial spores. These tests have demonstrated a significant log reduction in these key pathogens.
Since studies have shown that contamination of environmental surfaces in healthcare facilities with SARS-CoV-2 viral RNA is widespread, Diversey commissioned third-party testing of MoonBeam 3 in the U.S. and has also partnered with the highly respected Fujita Health University in Japan, to test the effectiveness of the MoonBeam 3 against SARS-CoV-2. The completed test results from Japan proved that MoonBeam 3 was effective against SARS-CoV-2 under a range of conditions with contact times as low as 4 seconds for a 6 log reduction.
This study validates that MoonBeam3 is effective against SARS-CoV-2, the pathogen that causes COVID-19.